Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pengcheng Shi

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
Journal of Clinical Laboratory Analysis|January 8, 2020
Long non-coding RNAE330013P06 promotes progression of breast cancer with type 2 diabetesRunqi Chen, Pengcheng Shi, Yan Zhang, et al.
Blood Cancer Journal|November 13, 2023
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort studyDan Xu, Ying Yang, Zhao Yin, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 2, 2022
Artificial Heterogeneous Interphase Layer with Boosted Ion Affinity and Diffusion for Na/K-Metal BatteriesYu Jiang, Yang Yang, Fangxin Ling, et al.
BMC Medicine|September 1, 2022
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trialXin Xu, Zhiping Fan, Yu Wang, et al.
Chinese Medical Journal|April 25, 2022
Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph- high-risk B-cell acute lymphoblastic leukemiaMenglin Fan, Yu Wang, Ren Lin, et al.
Transplantation and Cellular Therapy|September 1, 2022
Haplo-Peripheral Blood Stem Cell Plus Cord Blood Grafts for Hematologic Malignancies Might Lead to Lower Relapse Compared with Haplo-Peripheral Blood Stem Cell Plus Bone Marrow GraftsFen Huang, Xiangzong Zeng, Zhiping Fan, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2024
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemiaZhao Yin, Zurong Yao, Dandan Chen, et al.
Cancer|March 22, 2022
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemiaXiaoxia Chen, Junwei Huang, Na Xu, et al.
American Journal of Hematology|January 2, 2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trialHui Liu, Fen Huang, Yu Zhang, et al.
Cancer Letters|October 18, 2020
Angiogenic factor AGGF1 acts as a tumor suppressor by modulating p53 post-transcriptional modifications and stability via MDM2Wenxia Si, Bisheng Zhou, Wen Xie, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
Journal of Clinical Laboratory Analysis|January 8, 2020
Long non-coding RNAE330013P06 promotes progression of breast cancer with type 2 diabetesRunqi Chen, Pengcheng Shi, Yan Zhang, et al.
Blood Cancer Journal|November 13, 2023
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort studyDan Xu, Ying Yang, Zhao Yin, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 2, 2022
Artificial Heterogeneous Interphase Layer with Boosted Ion Affinity and Diffusion for Na/K-Metal BatteriesYu Jiang, Yang Yang, Fangxin Ling, et al.
BMC Medicine|September 1, 2022
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trialXin Xu, Zhiping Fan, Yu Wang, et al.
Chinese Medical Journal|April 25, 2022
Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph- high-risk B-cell acute lymphoblastic leukemiaMenglin Fan, Yu Wang, Ren Lin, et al.
Transplantation and Cellular Therapy|September 1, 2022
Haplo-Peripheral Blood Stem Cell Plus Cord Blood Grafts for Hematologic Malignancies Might Lead to Lower Relapse Compared with Haplo-Peripheral Blood Stem Cell Plus Bone Marrow GraftsFen Huang, Xiangzong Zeng, Zhiping Fan, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2024
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemiaZhao Yin, Zurong Yao, Dandan Chen, et al.
Cancer|March 22, 2022
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemiaXiaoxia Chen, Junwei Huang, Na Xu, et al.
American Journal of Hematology|January 2, 2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trialHui Liu, Fen Huang, Yu Zhang, et al.
Cancer Letters|October 18, 2020
Angiogenic factor AGGF1 acts as a tumor suppressor by modulating p53 post-transcriptional modifications and stability via MDM2Wenxia Si, Bisheng Zhou, Wen Xie, et al.
Pageof 19